Stocktoria
LIGAND PHARMACEUTICALS INC LGND
LIGAND PHARMACEUTICALS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $268.1M | $167.1M | $131.3M | $196.2M | $241.5M | $163.6M | $120.3M | $251.5M | $141.1M | $109.0M |
| R&D expense | $81.2M | $21.4M | $24.5M | $36.1M | $32.1M | $40.5M | $55.9M | $27.9M | $26.9M | $21.2M |
| Operating income | $41.0M | -$22.6M | $11.9M | $3.0M | $103.9M | $37.5M | $807.1M | $163.7M | $68.1M | $43.9M |
| Interest expense | — | — | $656,000 | $1.8M | $19.6M | $27.4M | $35.7M | $48.3M | $13.5M | $12.8M |
| Income tax | $34.5M | $6.5M | $9.8M | $41.2M | -$4.1M | -$5.3M | $167.3M | $30.0M | $44.7M | $10.3M |
| Net income | $124.5M | -$4.0M | $52.2M | -$33.4M | $57.1M | -$3.0M | $629.3M | $143.3M | $12.6M | -$1.6M |
| EPS (diluted) | $6.13 | $-0.22 | $2.94 | $-1.98 | $3.31 | $-0.18 | $31.85 | $5.96 | $0.53 | $-0.08 |
| Operating cash flow | $49.4M | $97.0M | $49.6M | $137.8M | $78.8M | $54.6M | -$29.3M | $194.1M | $88.6M | $63.0M |
| Free cash flow | $48.9M | $95.2M | $46.1M | $119.9M | $70.0M | $50.1M | -$31.9M | $193.2M | $86.4M | $61.2M |
| Cash & equivalents | $174.9M | $72.3M | $23.0M | $45.0M | $19.5M | $47.6M | $71.5M | $117.2M | $20.6M | $18.8M |
| Inventory | $9.1M | $14.1M | $24.0M | $13.3M | $27.3M | $26.5M | $7.3M | $7.1M | $4.4M | $1.9M |
| Total assets | $1.6B | $941.8M | $787.2M | $762.7M | $1.3B | $1.4B | $1.5B | $1.3B | $671.0M | $601.6M |
| Total liabilities | $543.4M | $111.3M | $86.3M | $165.2M | $476.4M | $652.8M | $727.7M | $699.9M | $252.4M | $230.7M |
| Shareholders' equity | $1.0B | $830.4M | $700.9M | $597.5M | $821.2M | $709.5M | $767.2M | $560.9M | $399.8M | $341.3M |
Growth · year-over-year · Revenue CAGR 10.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +60.4% | +27.3% | -33.1% | -18.8% | +47.7% | +36.0% | -52.2% | +78.2% | +29.5% | +51.5% |
| Net income growth | — | -107.7% | — | -158.4% | — | -100.5% | +339.1% | +1041.5% | — | -100.7% |
| EPS growth | — | -107.5% | — | -159.8% | — | -100.6% | +434.4% | +1024.5% | — | -100.7% |
| Free cash flow growth | -48.6% | +106.8% | -61.6% | +71.2% | +39.7% | — | -116.5% | +123.5% | +41.3% | +46.9% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.